Clinical Trial: Neoadjuvant Anti-PD1 in HCC
Study Status: Completed
Recruit Status: Completed
Condition:
Hepatocellular Carcinoma
HCC
Liver Cancer
Study Type: Interventional
Official Title: Neoadjuvant Immunotherapy With Anti-PD1 in Borderline Resectable Hepatocellular Carcinoma
Brief Summary:
This is a phase 2, single-arm trial designed to assess the clinical benefit of treatment with nivolumab administered in patients with untreated, borderline resectable HCC.
Read more